Mild Cognitive Impairment
Conditions
Brief summary
The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abnormal blood-based biomarker testing.
Detailed description
This study is conducted to evaluate whether a new approach to screening patients for cognitive decline in primary care practices helps with earlier detection of Alzheimer's Disease. As part of the study, the provider subjects will receive training about the PrecivityAD blood biomarker test offered by C2N Diagnostics. They will be able to order the PrecivityAD test for possible Alzheimer's disease if their patient has an abnormal screening for cognitive impairment and consents to this study. Patient subjects will have their blood drawn (1 teaspoon) for the PrecivityAD blood test and will be asked to complete a surveys before and after the blood drawn. They will receive follow up phone calls within 1 to 4 weeks after they discuss the results of their blood test with their primary care.
Interventions
DEVICEPrecivityAD
Measure risk for amyloid plaques in the brain and will include a test for certain genetic variants (specifically, ApoE proteins in the blood revealing APOE genotype) known to be associated with Alzheimer's disease.
Sponsors
Davos Alzheimer's Collaborative
Regenstrief Institute, Inc.
Indiana University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must be \> 65 years of age * Any gender * Is an established or new patient at one of the 6 participating IUHP PC sites * Is able to provide informed consent (research portion only for the biomarker consent) or has a Legally Authorized Representative (LAR) who can provide informed consent * Has a red DCA screening in the last 12 months (a score of 0 or 1 out of 5)
Exclusion criteria
* Patients who do not complete a DCA screening for any reason * Existing diagnosis of dementia documented in their medical record based on ICD-10 codes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients who are willing to have Blood Based Biomarkers Performed | Mar 31, 2023 to May 31, 2023 | Evaluate the feasibility and acceptability of implementing blood-based biomarker testing for Alzhiemer's Disease and Related Dementia in primary care practices |
Countries
United States
Outcome results
None listed